Meta Category: Healthcare

Key Highlights

  • Cochlear earns Recurring Revenue from upgrading the external sound processors used by its large base of implant recipients.
  • Its new Nexa implant system made up more than 95% of developed-market implants in FY2026, refreshing the product line.
  • FY2026 Underlying Profit fell 22% to A$322.4 million on Margin pressure, even as sales edged higher.
  • Cochlear (ASX:COH) is the world's leading maker of cochlear implants — devices that restore a sense of sound to people.

Cochlear (ASX:COH) is the world's leading maker of cochlear implants — devices that restore a sense of sound to people with severe hearing loss — and a member of the S&P/ASX 200 health care sector. Its Business has two parts: implanting devices in new recipients, and, over the following years, upgrading the external sound processors those recipients wear. Why hearing implant upgrades matter to Cochlear is central to its model, because each implant recipient becomes a long-term customer who periodically upgrades to newer sound processors, generating a stream of recurring, high-margin revenue that grows as the installed base of recipients expands.

The FY2026 result, for the year ended 30 June 2026, showed modest sales growth but a sharp fall in profit, as the launch of a new implant system and other pressures weighed on margins.

A year of margin pressure

Cochlear reported sales revenue of A$2.34 billion, up 2% in constant currency but down 1% on a reported basis. Underlying net profit after tax fell 22% to A$322.4 million, from A$414.5 million, and statutory net profit fell 62% to A$147.3 million. The gross margin declined to 71%, from 74%, which the company attributed to unfavourable foreign exchange, the costs of transitioning to a new product, and a shift in the mix of revenue by region.

The result, while at the top of a revised guidance range, reflected a difficult year for profitability. The company guided to a return to profit growth in FY2027, with underlying net profit of A$330–350 million, suggesting the pressures were substantially transitional. The launch of its new implant system was central to the year.

The two sides of the business

Cochlear's revenue comes from two main sources. The first is cochlear implants — the surgically implanted devices given to new recipients, whether children born with hearing loss or adults who have lost their hearing. Each implant is a significant sale, and growing the number of implants expands Cochlear's installed base of recipients.

The second, and in some ways more valuable, source is the recurring revenue from services and upgrades. The implanted part is designed to last a lifetime, but the external sound processor that pairs with it is upgraded periodically as technology improves. Every recipient in Cochlear's large and growing installed base is a potential upgrade customer, generating repeat, high-margin sales over many years. This recurring upgrade revenue is a key part of the Investment case, because it grows steadily as more people receive implants and as newer processors are released.

Why upgrades are so valuable

The upgrade cycle is what makes Cochlear's installed base so valuable. Once someone receives an implant, they remain a Cochlear customer for life, returning to upgrade their sound processor to newer models that offer better hearing, connectivity and features. This creates a recurring revenue stream that is more predictable and higher-margin than one-off device sales, and it compounds as the installed base grows year after year.

The risks

Cochlear faces several risks. Its profitability is sensitive to currency movements, given its global sales and Australian cost base, as FY2026 showed. Product transitions, like the Nexa launch, bring short-term costs and execution risk. The pace of new implants depends on awareness, diagnosis, funding and healthcare access, and reimbursement decisions by health systems and insurers affect demand.

Competition exists in cochlear implants and related hearing devices, and Cochlear must keep innovating to maintain its leading position and its premium pricing. Its premium valuation, reflecting its quality and growth record, leaves limited room for disappointment, as the profit fall and share reaction in FY2026 illustrated. Manufacturing, regulatory and quality risks apply to implantable medical devices, where safety is paramount. Broad healthcare-funding changes could affect Demand across its markets.